Effect of an injectable trace mineral supplement on the immune response of dairy calves.

On a spring calving, pastoral dairy farm, the first 40 heifer calves born after calving mid-point (50% of the herd calved) were blood sampled within 24 h. Thirty were selected, using stratified randomisation to form two equal groups (treatment and control) with the same distribution of serum total protein, copper, selenium, zinc, and manganese concentrations, age and breed. From the remaining 10 calves, five were randomly selected into a sentinel group to assess field exposure to Salmonella spp. All calves received two injections of a killed vaccine containing Salmonella spp. antigens at 2 and 6 weeks of age. Concurrently, the treatment group were injected with 1 mL/50 kg trace mineral supplement (TMS) containing 40 mg zinc, 10 mg manganese, 5 mg selenium, 15 mg copper per mL. Sentinel animals received no injections. All animals were bled from 2 to 9 weeks for assay of immune function. At three and four weeks, white blood cells from TMS calves had an increased percentage of cells phagocytosing (effect size = 9.36 and 4.35) and increased number of bacteria ingested per cell (effect size = 0.93 and 1.52). No differences were detected in gamma interferon response (effect size <0.15) or Salmonella sp. antibody titres (effect size <0.20).

Reduction in morbidity and mortality of dairy calves from an injectable trace mineral supplement.

The effect of a multimineral preparation on the health and growth of spring born, dairy calves was investigated on four New Zealand pastoral farms. Calves were randomly allocated injections within 24 hours of birth, 35 days and 70 days after birth. Injections contained 40 mg zinc, 10 mg manganese, 5 mg selenium, 15 mg copper and 5 mg chromium per ml (Multimin+Se+ Cu+Cr Cattle, Virbac South Africa) at 1 ml/50 kg body weight. Morbidity, mortality from natural challenge and growth rates were recorded for 140 days. There were no differences in morbidity and mortality within 48 hours of birth for treated calves compared with controls, P=0.192. Morbidity and mortality were highest at 3-35 days (7.5 per cent [95 per cent CI 5.00 to 9.99] treated calves sick and 15.6 per cent [95 per cent CI 12.48 to 18.73] controls sick, P<0.001). For this period, mortality was lower at 4.4 per cent (95 per cent CI 2.49 to 6.41) treated calves and 10.4 per cent (95 per cent CI 7.78 to 13.03) controls, P<0.001. Allowing for potential confounders, the adjusted OR of treated calves scouring between 3 and 35 days was 0.44 (95 per cent CI 0.24 to 0.82, P=0.009). Allowing for potential confounders, from 0 to 140 days a second model predicted treatment approximately halved the probability of morbidity and mortality (P<0.001). There was no difference in the daily rate of gain (0.67 kg/day [95 per cent CI 0.66 to 0.67] for treated calves).